TARGETED THERAPY IN COMPREHENSIVE MANAGEMENT OF METASTATIC COLON CANCER
- Authors: Feoktistova P.S.1, Karaseva V.V2, Khaylenko V.A2,3, Sinelnikova O.A2,3, Zharkova O.V4
-
Affiliations:
- KHMAO-Ugra Nizhnevartovsk Oncology Dispensary
- N.I. Pirogov Russian National Research Medical University
- N.N. Blokhin National Medical Research Center of Oncology
- Regional clinical oncology dispensary
- Issue: Vol 22, No 5 (2017)
- Pages: 266-273
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40382
- DOI: https://doi.org/10.18821/1028-9984-2017-22-5-266-273
- ID: 40382
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Polina S. Feoktistova
KHMAO-Ugra Nizhnevartovsk Oncology Dispensary
Email: paolaf@mail.ru
MD, Head of the Department of Chemotherapy, Nizhnevartovsk, 628615, Russian Federation Nizhnevartovsk, 628615, Russian Federation
V. V Karaseva
N.I. Pirogov Russian National Research Medical UniversityMoscow, 117997, Russian Federation
V. A Khaylenko
N.I. Pirogov Russian National Research Medical University; N.N. Blokhin National Medical Research Center of OncologyMoscow, 117997, Russian Federation; Moscow, 115478, Russian Federation
O. A Sinelnikova
N.I. Pirogov Russian National Research Medical University; N.N. Blokhin National Medical Research Center of OncologyMoscow, 117997, Russian Federation; Moscow, 115478, Russian Federation
O. V Zharkova
Regional clinical oncology dispensaryKemerovo, 650066, Russian Federation
References
- Grothey A., Sugrue M.M., Purdie D.M., Dong W., Sargent D., Hedrick E., Kozloff M. Bevacizumab beyond first progression in associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 2008; 26(33): 5326-34. doi: 10.1200/JCO.2008.16.3212.
- Van Cutsem E., Rivera F., Berry S. et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol. 2009; 20(11): 1842-7. doi: 10.1093/annonc/mdp233.
- Cohn A.L., Beckaii-Saab T., Bendell J.C. Clinical outcomes in bevacizumab (BV) - treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on beyond progression (BBP). J. Clin. Oncol. 2010: abstr 3596.
- Weitz J., Koch M., Debus J. et al. Colorectal cancer. Lancet. 2005; 365: 153-65.
- Falcone A. Treatment goals: What should we be aiming for? Alfredo Falcone - 2016.-WCGIC-mCRC-symp 03.
- Douillard J., Cunningham D., Roth A. et al. Irinotecan combined with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentrerandomised trial. Lancet. 2000; 355: 1041-7.
- De Gramont A., Figure A., Seymour M. et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000; 18: 2938-47.
- Tournigand C., André T., Achille E. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 2004; 22: 229-37.
- Grothey A., Sargent D., Goldberg R.et al. Survival of patients withadvanced colorectal cancer improves with the availability of fluorouracil leucovorin,irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 2004; 22; 1209-14.
- Douillard, J.Y., Siena S, Peeters M. et al. Impact of early tumor shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur. J. Cancer. 2015; 51: 1231-42.
- Van Cutsem E., Cervantes A., Adam R. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology. 2016: 1-38. doi: 10.1093/annonc/mdw235
- Venook, A. Niedzwiecki, D., Lenz, H.J. CALGB/SWOG 80405 Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J. Clin. Oncol. 2014. - 32 - 5s (ESMO - 2014. - abstract 5010)
- Heinemann V.,von Weikersthal L-F., Decker T. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 14: 1470-2045.
- Fedyanin M.Yu., Tryakin A.A., Tyulyandin S.A. First-line treatment of patients with metastatic inoperable colorectal cancer. Onkologicheskaya koloproktologiya. 2014; (4): 12-5. (in Russian) / Федянин, М.Ю. Трякин, А.А., Тюляндин, С.А. Первая линия лечения больных метастатическим неоперабельным раком толстой кишки. Онкологическая колопроктология. 2014; (4): 12-5.
- Artamonova E.V., Manzyuk L.V. Optimization second-line treatment of metastatic colorectal cancer: new opportunities for targeted therapy. Consilium Medicum. 2016; 1. http://con-med.ru/magazines/contemporary/contemporary-01-2016/optimizatsiya_vtoroy_linii_lecheniya_metastaticheskogo_kolorektalnogo_raka_novye_vozmozhnosti_target/ (in Russian) /Артамонова Е.В., Манзюк Л.В. Оптимизация второй линии лечения метастатического колоректального рака: новые возможности таргетной терапии. Consilium Medicum. 2016; 1. Режим доступа: http://con-med.ru/magazines/contemporary/contemporary-01-2016/optimizatsiya_vtoroy_linii_lecheniya_metastaticheskogo_kolorektalnogo_raka_novye_vozmozhnosti_target/